	US 11,718,879 B2
	Non-coding RNAS (NCRNA) for the diagnosis of cognitive disorders
Hueseyin Firat, Huningue (FR); Saliha Moussaoui, Bartenheim (FR); and Eric Schordan, Wentzwiller (FR)
Assigned to AMONETA DIAGNOSTICS, Huningue (FR)
Appl. No. 16/644,812
Filed by AMONETA DIAGNOSTICS, Huningue (FR); Hueseyin Firat, Huningue (FR); Saliha Moussaoui, Bartenheim (FR); and Eric Schordan, Wentzwiller (FR)
PCT Filed Sep. 5, 2018, PCT No. PCT/EP2018/073905 § 371(c)(1), (2) Date Mar. 5, 2020, PCT Pub. No. WO2019/048500, PCT Pub. Date Mar. 14, 2019.
Claims priority of provisional application 62/554,427, filed on Sep. 5, 2017.
Prior Publication US 2021/0071252 A1, Mar. 11, 2021
Int. Cl. C12Q 1/6883 (2018.01)

CPC C12Q 1/6883 (2013.01) [C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)]

3 Claims

1. A method of detecting levels of expression of lncRNAs in a lncRNA signature, comprising:

(a) isolating a biological sample from a subject, wherein the biological sample is selected from blood, plasma, and serum, and the subject is human;

(b) detecting levels of expression of lncRNAs in a LncRNA signature in the biological sample from said subject, wherein the lncRNA signature comprises 13 lncRNAs of lnc-DLGS5-1:1, lnc-EBLN1-1:4, lnc-FAT1-7:2, lnc-PRR5-5:1, lnc-RBKS-6:1, lnc-FOXD4L5-35:1, lnc-TENM3-3:3, lnc-FAM133B-2:1, lnc-ZNF726-1:3, lnc-AP3M1-1:1, lnc-DUSP10-6:1, lnc-TPPP-1:2, and LINC01206:20.